Description:

Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01752205

Link:

https://clinicaltrials.gov/show/NCT01752205

Keywords:
Versions (1) ▾
  1. 12/8/19
Copyright Holder:
See clinicaltrials.gov
Uploaded on:

December 8, 2019

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Esophageal Squamous Carcinoma NCT01752205

Eligibility Esophageal Squamous Carcinoma NCT01752205

Inclusion Criteria
1. histologically confirmed squamous cell carcinoma of esophagus or esophagogastric junction
2. age >= 18
3. ecog ps 0-2
4. ineligibility for surgery
5. no prior palliative therapy
6. at least one bidimensionally measurable disease as defined by recist ver 1.1
7. adequate organ function for treatment
absolute neutrophil count (anc)>=1000cells/mm3
platelets >=100000 cells/mm3
estimated creatinine clearance>=50ml/min, or serum creatinine<1.5 x institution upper limit of normal
bilirubin=<1.5 x upper limit of normal(uln)
ast(sgot)=<2.5 x uln (5.0xuln if hepatic metastases)
alt(sgpt)=<2.5 x uln (5.0xuln if hepatic metastases)
12-lead electrocardiogram(ecg) with normal tracing or non-clinically significant changes that do not require medical intervention
qtc interval =<470 msec and without history of torsades de points or other symptomatic qtc abnormality
lvef (by muga or echocardiogram) of >=50%.
8. the patient has provided signed informed consent and is amenable to compliance with protocol schedules and testing.
Exclusion Criteria
1. previous treatment with small molecule egfr tyrosine kinase inhibitors
2. any major operation within 4 weeks of baseline disease assessment
3. any clinically significant gastrointestinal abnormalities which may impair intake or absorption of the study drug
4. cns metastasis with continuous corticosteroid use within 4 weeks of baseline disease assessment
5. patients with known interstitial lung disease
6. patients with uncontrolled or significant cardiovascular disease (ami within 12 months,unstable angina within 6 months, nyha class iii, iv congestive heart failure or left ventricular ejection fraction below local institutional lower limit of normal or below 45%, congenital long qt syndrome, any significant ventricular arrhythmia, any uncontrolled second or third degree heart block, uncontrolled hypertension)
7. previous or concurrent malignancy except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and without evidence of recurrence for at least 5 years prior to study entry.
8. pregnant or breast-feeding women
9. other severe acute or chronic medical condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry into this trial.